Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 29
1974 11
1975 25
1976 11
1977 18
1978 34
1979 21
1980 19
1981 28
1982 27
1983 36
1984 32
1985 34
1986 55
1987 42
1988 33
1989 35
1990 37
1991 25
1992 32
1993 38
1994 34
1995 24
1996 20
1997 15
1998 24
1999 18
2000 14
2001 31
2002 25
2003 27
2004 27
2005 34
2006 23
2007 31
2008 25
2009 23
2010 26
2011 32
2012 22
2013 24
2014 22
2015 16
2016 20
2017 22
2018 18
2019 17
2020 15
2021 14
2022 12
2023 8
2024 9
2025 12
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,251 results

Results by year

Filters applied: . Clear all
Page 1
Analgesic efficacy of naproxen-codeine, naproxen+dexamethasone, and naproxen on myofascial pain: A randomized double-blind controlled trial.
Cigerim L, Kaplan V. Cigerim L, et al. Cranio. 2023 Mar;41(2):119-125. doi: 10.1080/08869634.2020.1824411. Epub 2020 Sep 17. Cranio. 2023. PMID: 32941116 Clinical Trial.
OBJECTIVE: To assess the effects of naproxen sodium-codeine phosphate, naproxen sodium-dexamethasone, and naproxen sodium on myofascial pain. ...A total of 169 patients were randomly divided into four groups and received the following treatments: Group A: …
OBJECTIVE: To assess the effects of naproxen sodium-codeine phosphate, naproxen sodium-dexamethasone, and naproxen sodi …
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, Popmihajlov Z, Peloso PM. Balazcs E, et al. BMC Musculoskelet Disord. 2016 Oct 13;17(1):426. doi: 10.1186/s12891-016-1275-5. BMC Musculoskelet Disord. 2016. PMID: 27737664 Free PMC article. Clinical Trial.
In Part I, subjects were randomized to naproxen 1000 mg; etoricoxib 60 mg, and 90 mg. In Part II, naproxen and etoricoxib 90 mg subjects continued on the same treatment; subjects on etoricoxib 60 mg either continued on 60 mg or escalated to 90 mg. Part I (6 weeks) a …
In Part I, subjects were randomized to naproxen 1000 mg; etoricoxib 60 mg, and 90 mg. In Part II, naproxen and etoricoxib 90 m …
Clinical and objective assessments of naproxen through 5 years of clinical experience.
Katona G. Katona G. Arzneimittelforschung. 1975 Feb;25(2A):327-32. Arzneimittelforschung. 1975. PMID: 807224 Clinical Trial.
D-2-(6'-Methoxy-2'-naphthyl)-propionic acid (naproxen) is a relatively well-known non-hormonal anti-inflammatory agent useful for long-term usage. ...The efficacy and tolerance of naproxen have been studied in the following indications: rheumatoid arthritis, osteoar …
D-2-(6'-Methoxy-2'-naphthyl)-propionic acid (naproxen) is a relatively well-known non-hormonal anti-inflammatory agent useful for lon …
Pharmacokinetic properties and clinical efficacy of once-daily sustained-release naproxen.
Kelly JG, Kinney CD, Devane JG, Mulligan S, Colgan BV. Kelly JG, et al. Eur J Clin Pharmacol. 1989;36(4):383-8. doi: 10.1007/BF00558300. Eur J Clin Pharmacol. 1989. PMID: 2661242 Clinical Trial.
As is the case with conventional-release naproxen, food decreased the rate but not the extent of absorption of the sustained-release formulation. ...The results suggest that sustained-release naproxen sodium has potential for use as a once-daily treatment for inflam …
As is the case with conventional-release naproxen, food decreased the rate but not the extent of absorption of the sustained-release …
A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain.
Bergmann JF, Chassany O, Gandiol J, Deblois P, Kanis JA, Segrestaa JM, Caulin C, Dahan R. Bergmann JF, et al. Clin Trials Metaanal. 1994 Apr;29(1):41-7. Clin Trials Metaanal. 1994. PMID: 10150184 Clinical Trial.
Visual analogue scales of pain before and 30, 60, 120 and 180 min after the intake of naproxen and placebo were recorded. As an analgesic, naproxen was more effective than placebo in both groups of patients (p = 0.001). For naproxen as well as for placebo, th …
Visual analogue scales of pain before and 30, 60, 120 and 180 min after the intake of naproxen and placebo were recorded. As an analg …
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P Jr, Reicin AS, Giannini EH. Reiff A, et al. J Rheumatol. 2006 May;33(5):985-95. Epub 2006 Apr 1. J Rheumatol. 2006. PMID: 16583464 Clinical Trial.
The relative rates of response compared to naproxen were 0.81 (95% CI 0.61, 1.07) and 0.98 (95% CI 0.76, 1.26) for LD- and HD-rofecoxib, respectively. Both rofecoxib doses were not inferior to naproxen. Patients (N=227) entering the extension received HD-rofecoxib o …
The relative rates of response compared to naproxen were 0.81 (95% CI 0.61, 1.07) and 0.98 (95% CI 0.76, 1.26) for LD- and HD-rofecox …
Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.
Miner P Jr, Plachetka J, Orlemans E, Fort JG, Sostek M. Miner P Jr, et al. Aliment Pharmacol Ther. 2010 Aug;32(3):414-24. doi: 10.1111/j.1365-2036.2010.04361.x. Epub 2010 May 18. Aliment Pharmacol Ther. 2010. PMID: 20491746 Clinical Trial.
METHODS: In this Phase I, randomized, open-label study, 28 healthy adults received PN 400 b.d. (naproxen 500 mg plus esomeprazole 10, 20 and 30 mg) and non-EC naproxen 500 mg b.d. plus EC esomeprazole 20 mg o.d., each for 9 days in a crossover fashion. ...RESULTS: D …
METHODS: In this Phase I, randomized, open-label study, 28 healthy adults received PN 400 b.d. (naproxen 500 mg plus esomeprazole 10, …
Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Kivitz A, et al. J Fam Pract. 2002 Jun;51(6):530-7. J Fam Pract. 2002. PMID: 12100776 Clinical Trial.
The incidence of endoscopically proven ulcers was significantly higher in the naproxen group than in the 5- and 10-mg valdecoxib groups, but not in the 20-mg valdecoxib group. ...Upper gastrointestinal tract safety of valdecoxib (5 and 10 mg) was comparable to that of plac …
The incidence of endoscopically proven ulcers was significantly higher in the naproxen group than in the 5- and 10-mg valdecoxib grou …
A comparative, double-blind trial with proquazone and naproxen in the treatment of rheumatoid arthritis.
Bragstad A. Bragstad A. Scand J Rheumatol Suppl. 1978;(21):33-5. doi: 10.3109/03009747809095673. Scand J Rheumatol Suppl. 1978. PMID: 356240 Clinical Trial.
In a double-blind trial lasting 6 months, 36 patients with classical or definity rheumatoid arthritis were divided into two groups, one receiving 3x300 mg proquazone/day and the other 2x250 mg naproxen plus one placebo capsule/day. Efficacy parameters were assessed and lab …
In a double-blind trial lasting 6 months, 36 patients with classical or definity rheumatoid arthritis were divided into two groups, one rece …
1,251 results